Spinnaker Life Sciences Strategy Consulting

Executive leadership teams juggle countless initiatives, often leading to misalignment between financial goals and strategic priorities. At Spinnaker, we specialize in bridging this gap. From crafting operating budgets that align with corporate strategies to refining development scenarios, we help organizations realign, innovate, and seize growth opportunities. Our approach includes fostering consistent, transparent discussions among executive teams and ensuring clarity with the Board of Directors – essential for sustained success. We specialize in navigating through challenging waters. Ready to explore how we can support your journey? Visit our website at the link below. https://lnkd.in/eR-YXrzS #Biotech #CorporateStrategy #FPA Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Last week's Com-X gathering in San Diego, sponsored by Spinnaker, was attended by two of our Managing Partners, Harris Kaplan and Dane C.. The event proved to be a great success, featuring insightful discussions with some of San Diego’s foremost life sciences executives, as well as an engaging presentation by Bill Rastetter. Thank you to Com-X Network San Diego for the opportunity to participate in this outstanding event!   #Biotech #LifeSciences #ComX #BioPharma #Networking

Over the last 15 years, about half of all new product launches have fallen short of their pre-launch forecasts. In today’s high-stakes healthcare market, achieving new product success requires more than clinical innovation and a better product—it’s about recognizing and mastering the human side of change. Success depends on understanding what it takes to shift people’s behavior away from the status quo. Spinnaker’s RAMPx model, adapted specifically for the life sciences from Everett Rogers' Diffusion of Innovation framework, provides a data-driven approach to realistically assess and enhance a new product’s future commercialization potential. By aligning product design to overcome people’s adoption barriers—such as ease of adoption and perceived risk—companies can accelerate uptake by clearly demonstrating a new product’s value in a crowded and cautious market. Citeline Commercial In Vivo has made both Part 1 and Part 2 of this series available outside its paywall. We invite you to explore these insights and connect with Harris Kaplan to discuss how to achieve meaningful impact in today’s value-driven healthcare environment—and how the RAMPx model can help your company succeed. Click the link below for Part 2. https://lnkd.in/eabpFkNX #NewProduct #Commercialization #LaunchRorecast #Healthcare #Biotech Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Yesterday morning, we were excited to celebrate Cellbricks Therapeutics opening their first US office in "the most innovative square mile on the planet" with a ribbon-cutting ceremony led by the Mayor of Berlin, Kai Wegner. Their work in 3D bioprinting is redefining the possibilities of next-gen tissue engineering, and the opening of their Kendall office marks a major milestone in their global expansion. We're thrilled to support their continued growth and success.   #BioPrinting #3DPrinting #HealthcareInnovation #Cellbricks #CambridgeMA #Biotech #LifeSciences #TissueEngineering #RegenerativeMedicine

The Inflation Reduction Act (IRA) of 2022, the rise of value-based care models, and increasing global reliance on Health Technology Assessments (HTAs) have heightened scrutiny on pharmaceutical pricing. In this new environment, Health Economics and Outcomes Research (HEOR) is cementing itself as an valuable framework for justifying costs. With advancements in decentralized trials (DCTs) and AI, HEOR’s role is likely to expand, enabling more efficient data collection and predictive analysis of real-world patient outcomes. Click the link below to learn more. https://lnkd.in/ebGjhgQm #HEOR #HealthEconomicsAndOutcomesResearch #InflationReductionAct #HealthTechnologyAssessments Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Welcome to the November edition of the Spinnaker Insights newsletter. This month, Managing Partner Harris Kaplan provides insight into why new products struggle to achieve success in today's healthcare system. #LifeSciences #Healthcare #Commercialization

Congratulations to the entire ARS Pharmaceuticals, Inc. team on the news of their exclusive agreement with ALK to commercialize neffy in Europe, Canada, and other OUS geographies. Neffy has the potential to change the lives of millions at risk of anaphylaxis with a needle free, easy to carry, and easy to use device. This agreement will help bring neffy to even more patients around the world. #neffy #foodallergy #allergies #anaphylaxis #Spinnaker

At Spinnaker, we’re focused on helping our clients achieve sustainable success in an increasingly complex healthcare landscape. We’re pleased to share that Managing Partner Harris Kaplan’s recent article in In Vivo by Citeline Commercial tackles a key challenge in today’s healthcare landscape: creating product strategies that succeed in the “Show Value or Underperform” era. With 125 product launches and 40 years of commercialization experience, Harris highlights how the evolving commercial environment is reshaping how companies must approach product development and commercialization. This two-part article, “Commercialization 3.0: Achieving New Product Success in Health Care’s New Era," explores why so many products fail to meet ambitious pre-launch forecasts, how healthcare stakeholders’ decision criteria have shifted, and the essential steps companies must take to build stronger value propositions. Part 1 examines the core drivers behind underperformance in new product launches. It challenges traditional thinking and provides actionable insights into the often-overlooked barriers that prevent new products from gaining traction. Part 2, available in two weeks, introduces a structured framework designed to help organizations align their value propositions more closely with the expectations of today’s healthcare stakeholders. As Harris mentions, in today’s environment, a new product’s toughest competitor may not be another drug or device, but the time and cost associated with its evaluation. Physicians must often weigh the opportunity costs of engaging with new products, while patients consider the practicalities of accessing new therapies. Commercialization 3.0 shifts the focus beyond the payer-centric “Access Model” of Commercialization 2.0 and the sales-driven “Military Model” of Commercialization 1.0 to emphasize a more nuanced, stakeholder-centric approach. In Vivo has made both parts of the article available outside its paywall. We invite you to read Part 1 through the link below and connect with Harris Kaplan for deeper insights, discussion, or to receive Part 2 directly. We’re eager to hear your perspectives on how companies can achieve meaningful impact in today’s value-driven healthcare market. #newproduct #commercialization #launchforecast #healthcare https://lnkd.in/egPnfh4T

For pre-commercial companies, identifying the best market opportunities among multiple targets and indications can be challenging, especially when resource constrained. This challenge is compounded by the complexity in assessing different treatment pathways, efficacy benchmarks, and competitor timelines. Our firm’s expertise in developing methodologies that bridge scientific and commercial considerations will enable your organization to gain insights into nuanced market analyses, existing treatment pathways, key benchmarks, and competitor clinical timelines. Through our comprehensive analysis we can shape informed strategies that will empower your leadership team to make strategic portfolio decisions.     Interested in learning about how we help companies develop short- and long-term portfolio decisions? Visit our website at the link below. https://lnkd.in/eZxY9tBA #Biotech #PortfolioStrategy #MarketAnalysis #ClinicalDevelopment

Welcome to the September edition of the Spinnaker Insights newsletter. This month, we explore how biopharma companies and investors can deepen their understanding of stakeholder dynamics, addressing common pitfalls that contribute to new-product revenue underperformance and enhancing the accuracy of forecasts. #LifeSciences #CommercialStrategy #InvestmentStrategy